Enlivex Therapeutics Ltd (ENLV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enlivex Therapeutics Ltd (ENLV) has a cash flow conversion efficiency ratio of -0.131x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.30 Million ≈ $-6.15K USD) by net assets (ILA17.48 Million ≈ $46.87K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Enlivex Therapeutics Ltd to measure how much of total assets are equity-financed.
Enlivex Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Enlivex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check total reinvestment intensity of Enlivex Therapeutics Ltd to assess the company's total reinvestment commitment from operating cash flow.
Enlivex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enlivex Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TRU PRECIOUS METALS CORP.
F:706
|
0.050x |
|
DSJ Keep Learning Limited
NSE:KEEPLEARN
|
0.014x |
|
Baillie Gifford UK Growth Fund PLC
LSE:BGUK
|
0.006x |
|
Lavoro Limited Class A Ordinary Shares
NASDAQ:LVRO
|
-0.676x |
|
Argeo AS
OL:ARGEO
|
-0.020x |
|
Oakajee Corporation Ltd
AU:OKJ
|
-0.189x |
|
Oculus VisionTech Inc
V:OVT
|
-0.001x |
|
Saferoads Holdings Ltd
AU:SRH
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Enlivex Therapeutics Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Enlivex Therapeutics Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Enlivex Therapeutics Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA23.59 Million ≈ $63.24K |
ILA-13.01 Million ≈ $-34.87K |
-0.551x | +29.47% |
| 2023-12-31 | ILA30.08 Million ≈ $80.65K |
ILA-23.52 Million ≈ $-63.06K |
-0.782x | -85.55% |
| 2022-12-31 | ILA56.84 Million ≈ $152.39K |
ILA-23.95 Million ≈ $-64.22K |
-0.421x | -104.29% |
| 2021-12-31 | ILA85.04 Million ≈ $227.99K |
ILA-17.54 Million ≈ $-47.03K |
-0.206x | +33.49% |
| 2020-12-31 | ILA35.49 Million ≈ $95.14K |
ILA-11.01 Million ≈ $-29.51K |
-0.310x | +50.30% |
| 2019-12-31 | ILA11.28 Million ≈ $30.25K |
ILA-7.04 Million ≈ $-18.88K |
-0.624x | -91.63% |
| 2018-12-31 | ILA9.71 Million ≈ $26.02K |
ILA-3.16 Million ≈ $-8.47K |
-0.326x | +83.79% |
| 2017-12-31 | ILA3.16 Million ≈ $8.48K |
ILA-6.35 Million ≈ $-17.03K |
-2.009x | -12.84% |
| 2016-12-31 | ILA8.70 Million ≈ $23.32K |
ILA-15.49 Million ≈ $-41.52K |
-1.780x | -140.94% |
| 2015-12-31 | ILA17.93 Million ≈ $48.08K |
ILA-13.25 Million ≈ $-35.52K |
-0.739x | -414.03% |
| 2014-12-31 | ILA30.67 Million ≈ $82.24K |
ILA-4.41 Million ≈ $-11.82K |
-0.144x | +7.69% |
| 2013-12-31 | ILA5.55 Million ≈ $14.89K |
ILA-865.00K ≈ $-2.32K |
-0.156x | +92.16% |
| 2012-12-31 | ILA75.00K ≈ $201.07 |
ILA-149.00K ≈ $-399.46 |
-1.987x | -- |
About Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee o… Read more